- Home
- NBBK vs GERN Comparison
NBBK vs GERN Comparison
Compare NBBK & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- GERN
- Stock Information
- Founded
- NBBK 1892
- GERN 1990
- Country
- NBBK United States
- GERN United States
- Employees
- NBBK N/A
- GERN N/A
- Industry
- NBBK
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- NBBK
- GERN Health Care
- Exchange
- NBBK Nasdaq
- GERN Nasdaq
- Market Cap
- NBBK 687.7M
- GERN 700.6M
- IPO Year
- NBBK N/A
- GERN 1996
- Fundamental
- Price
- NBBK $16.89
- GERN $1.17
- Analyst Decision
- NBBK Buy
- GERN Buy
- Analyst Count
- NBBK 1
- GERN 8
- Target Price
- NBBK $20.00
- GERN $3.71
- AVG Volume (30 Days)
- NBBK 247.3K
- GERN 9.0M
- Earning Date
- NBBK 07-23-2025
- GERN 08-06-2025
- Dividend Yield
- NBBK N/A
- GERN N/A
- EPS Growth
- NBBK 340.77
- GERN N/A
- EPS
- NBBK 1.33
- GERN N/A
- Revenue
- NBBK $179,119,000.00
- GERN $116,293,000.00
- Revenue This Year
- NBBK N/A
- GERN $161.44
- Revenue Next Year
- NBBK N/A
- GERN $53.06
- P/E Ratio
- NBBK $12.73
- GERN N/A
- Revenue Growth
- NBBK 28.24
- GERN 22264.04
- 52 Week Low
- NBBK $15.09
- GERN $1.09
- 52 Week High
- NBBK $21.05
- GERN $4.89
- Technical
- Relative Strength Index (RSI)
- NBBK 35.03
- GERN 39.34
- Support Level
- NBBK $17.87
- GERN $1.20
- Resistance Level
- NBBK $18.70
- GERN $1.37
- Average True Range (ATR)
- NBBK 0.51
- GERN 0.08
- MACD
- NBBK -0.24
- GERN -0.01
- Stochastic Oscillator
- NBBK 4.89
- GERN 28.57
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.